Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, is broadening the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. The company announced May 11 that it has developed a fatigue recognition system using speech analytics and proprietary artificial intelligence models, according to a news release (https://ibn.fm/4KNzG).
The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice samples.
Management says the system is intended for deployment in industries where alertness and operational safety are closely monitored, including mining, aviation, transportation and construction.
The announcement reflects a broader strategy by MindBio to position voice analytics as a scalable alternative to conventional impairment screening methods such as breathalyzers, saliva tests, urine analysis and laboratory-based toxicology testing. Rather than relying on physical samples, the company’s platform analyzes speech characteristics captured through a microphone and processes the audio using machine learning models trained on large voice datasets.
MindBio says its existing prediction platform has been developed using more than 50 million data points and evaluates more than 140 acoustic markers associated with intoxication and neurological impairment.
The newly announced fatigue detection module expands the company’s commercial focus beyond alcohol and drug screening into a broader workplace monitoring category that includes alertness and cognitive readiness.
In its recent patent application, titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics,” the company outlined claims related to identifying fatigue and impairment from voice analysis using short spoken phrases or pangrams. Management described the filing as part of a broader intellectual property strategy around AI-powered diagnostics and speech-based health analysis.
Chief Executive Officer Justin Hanka said the company sees an opportunity to expand into the digital health diagnostics market through non-invasive detection systems that can operate in real-time workplace environments.
“The digital health diagnostics market represents a significant opportunity for MindBio to leverage its non-invasive diagnostics technology with a first mover advantage in the detection of neurologically active substances and now fatigue from voice and AI,” Hanka said. “The company has claimed 15 world firsts in its recent patent application filing and is progressing towards commercialisation with the development of its Edge AI Intoxication & Fatigue Detection Kiosks.”
The company has stated that commercial testing of its Edge AI kiosk hardware and software remains on schedule for late Q2 2026.
MindBio’s initial commercial emphasis has centered on mining operations, particularly in South America, where employers face strict workplace safety requirements and large operational workforces. Mining sites often require routine alcohol and drug screening because impairment-related incidents can create operational shutdowns, financial losses and worker safety risks. Traditional testing methods can also create logistical bottlenecks in remote industrial settings where thousands of workers may need to be screened regularly.
MindBio’s proposed system is designed to allow workers to provide a brief voice sample at an entry-point kiosk, with the AI model then generating an immediate assessment based on detected speech patterns.
The company argues that voice-based testing may offer a more scalable approach for organizations seeking frequent or high-volume screening without relying exclusively on laboratory infrastructure or invasive testing procedures.
Fatigue monitoring may also represent a significant adjacent opportunity for industrial operators. In sectors such as aviation, trucking and mining, fatigue-related incidents remain a major workplace safety concern, particularly in environments involving long shifts, remote operations or continuous production schedules.
The broader workplace testing market has continued to expand as employers increase investment in safety compliance and operational risk management. MindBio is entering a market that includes traditional testing equipment manufacturers, laboratory service providers and emerging AI-based diagnostic companies. Its differentiation strategy centers on speed, portability and non-invasive analysis delivered through voice recognition technology.
Beyond mining, the company has identified additional potential applications across aviation, law enforcement, construction, transportation and call centers, where large-scale screening can be difficult or expensive using traditional methods. Management has also discussed the possibility of broader health and wellness applications tied to speech analytics, although the company’s near-term commercial priorities remain focused on intoxication and fatigue detection.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and…
Unlike prostate, colon and breast cancers, the screening for lung cancer hasn’t been very successful. This is largely because screening focuses…
CDIO’s vision reflects a broader shift taking place across the healthcare industry toward predictive and…
Research supports the urgent need for more effective tools to identify the risk of cardiovascular…
Seasonal influenza often spreads rapidly, and timely data can help policymakers and the health care…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. During…